Clinical Trials Browser

NCT03155620 2026-04-14

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04394858 2026-04-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

46 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Phase 2 Recruiting

57 enrolled

CNS

Glioma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase 2 Recruiting

78 enrolled

CNS

Glioblastoma

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Phase 2 Active not recruiting

89 enrolled

CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03212742 2025-12-04

OLA-TMZ-RTE-01

Phase 1/2 Active not recruiting

91 enrolled

CNS

Glioma

NCT03561870 2025-09-12

OLAGLI

Phase 2 Completed

35 enrolled

CNS

Glioma, Recurrence

NCT02974621 2025-08-03

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Active not recruiting

70 enrolled 15 charts

CNS

Glioblastoma

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

Phase EARLY_PHASE1 Recruiting

10 enrolled

CNS

Glioblastoma, Recurrence

NCT04614909 2025-02-28

Study of Pamiparib in Newly Diagnosed and rGBM

Phase EARLY_PHASE1 Active not recruiting

45 enrolled

CNS

Glioblastoma

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

6 enrolled 12 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03991832 2024-07-18

SOLID

Phase 2 Recruiting

58 enrolled

CNSGastrointestinal

Glioma, Cholangiocarcinoma

NCT01390571 2018-02-05

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Phase 1 Completed

34 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma